Sangamo BioSciences Acquires Ceregene for $1,000,000

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    9381 Judicial Drive San Diego, CA 92121
  • Company Description
    Using gene therapy delivery systems, Ceregene’s primary focus is the discovery and development of novel genetic therapeutics for the treatment of neurological disorders. Ceregene aims to be the leader in the field of Central Nervous System (CNS) disease treatment using molecular medicine, an area of great unmet medical need.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Under the terms of the definitive agreement Sangamo will issue to the stockholders of Ceregene 100,000 shares of Sangamo’s common stock, which represents less than 0.2 percent of Sangamo’s total shares outstanding. In addition, Sangamo has agreed to make contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of certain existing products of Ceregene.

Trending on Xconomy